SC
AKRO

Shay Capital’s Akero Therapeutics AKRO Stock Holding History

Shay Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,000
Closed -$303K – 274
2024
Q1 		$303K Buy
+12,000
New +$288K 0.05% 253

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Shay Capital's AKRO Position: Q2 2024 in Review

Shay Capital sold out of Akero Therapeutics (AKRO) in Q2 2024, closing a stake of 12,000 shares — an estimated $303K sold.

Shay Capital first reported a position in AKRO in Q1 2024 and held it in 1 quarter. The position peaked at $303K in Q1 2024. 153 funds tracked by Wall St. Rank hold AKRO as of Q2 2024.

  • Shay Capital reported no remaining Akero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Shay Capital sold 12,000 Akero Therapeutics shares in Q2 2024, an estimated $303K.
  • Shay Capital first reported a position in Akero Therapeutics in Q1 2024 and held it in 1 quarter.
  • Shay Capital's Akero Therapeutics position peaked at $303K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2024.

Based on Shay Capital's 13F filing for Q2 2024, filed 14 Aug 2024.